Physician profile
John T Abe
NPI 1578542569
$22,819.56
in general payments reported to CMS, 2019-2025
35 companies · $1,534 in 2025
The $1,534 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $755 · 2020: $333 · 2021: $36.10 · 2022: $1,670 · 2023: $17K · 2024: $1,639 · 2025: $1,534.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $15K · Food and Beverage: $4,011 · Travel and Lodging: $964.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $15,051.38 |
| Food and Beverage | $4,011.18 |
| Travel and Lodging | $963.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $17,410.12 | 2022-2024 | Da Vinci Surgical System, Ion |
| Glaxosmithkline, LLC. | $1,703.67 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals Lp | $820.14 | 2019-2025 | Airsupra, Breztri, Fasenra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $524.36 | 2023-2025 | Ofev, Jardiance, Jascayd |
| Insmed, INC. | $220.36 | 2019-2025 | Arikayce, Brinsupri |
| Harmony Biosciences LLC | $206.99 | 2020-2024 | Wakix |
| Haemonetics Corporation | $146.71 | 2023-2025 | Teg6s Hemostasis System |
| Abiomed | $141.50 | 2022 | |
| Galvanize Therapeutics, INC | $135.00 | 2024 | Aliya System |
| Amgen INC. | $129.18 | 2022-2025 | Tezspire, Repatha |
| Siemens Medical Solutions USA, INC. | $128.94 | 2024 | |
| Pinnacle Biologics, INC | $125.27 | 2019 | |
| Boston Scientific Corporation | $119.19 | 2019-2023 | Eluvia |
| Novartis Pharmaceuticals Corporation | $110.30 | 2019-2020 | |
| Resmed Corp | $106.70 | 2025 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $104.55 | 2023-2025 | |
| Electromed, INC. | $91.55 | 2023-2025 | Smartvest |
| Covidien Lp | $87.39 | 2019-2020 | |
| Inspire Medical Systems, INC. | $66.92 | 2024-2025 | Inspire |
| Merck Sharp & Dohme LLC | $57.19 | 2019-2022 | |
| Mylan Specialty L.P. | $54.89 | 2019-2022 | |
| Irhythm Technologies, INC. | $46.15 | 2023 | Zio Xt Patch |
| Genentech USA, INC. | $40.64 | 2020 | |
| Janssen Pharmaceuticals, INC | $34.92 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $30.34 | 2019 | |
| Gilead Sciences, INC. | $28.47 | 2025 | |
| Tetraphase Pharmaceuticals, INC. | $22.52 | 2019 | |
| Pulmonx Corporation | $21.82 | 2020 | |
| Abbott Laboratories | $18.19 | 2024 | Mitraclip |
| United Therapeutics Corporation | $18.15 | 2019 | |
| Scpharmaceuticals INC. | $16.74 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $14.75 | 2019 | |
| Circassia INC. | $13.53 | 2019 | |
| Medtronic Vascular, INC. | $13.35 | 2019 | |
| Inogen, INC. | $9.07 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Abe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.